The SDF-1 3'A Genetic Variation Is Correlated with Elevated Intra-tumor Tissue and Circulating Concentration of CXCL12 in Glial Tumors
Hossein Khorramdelazad,1,*Vajihe Yousefi,2Gholamhossein Hassanshahi,3
1. Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran 2. Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Introduction: Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are malignant glial tumors. CXCL12 (SDF-1) is involved in immune responses and has been associated with tumorigenesis. This study investigated the association of the SDF-1 3'A genetic variation with circulating and intra-tumor CXCL12 levels in Iranian patients with AA and GBM.
Methods: Tumor tissue and peripheral blood samples were collected from 123 patients and 189 healthy controls. Serum CXCL12 was measured by ELISA, tumor CXCL12 was assessed by Western blotting, and the SDF-1 3'A polymorphism was detected using PCR-RFLP.
Results: A significant difference was observed in the frequencies of the A/A, A/G, and G/G genotypes and A and G alleles between patients and controls. CXCL12 levels were elevated in both the circulation and tumor tissue of patients with malignant glial tumors.
Conclusion: CXCL12 and its SDF-1 3'A polymorphism may play a fundamental role in the pathogenesis of malignant glial tumors. CXCL12 could potentially serve as a beneficial biological marker in the diagnosis of these tumors.